Stocktoria
Coya Therapeutics, Inc. COYA
Coya Therapeutics, Inc. (COYA) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $7.9M at a -267.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.882 |
| Retained earnings / assets | -1.24 |
| EBIT / assets | -0.452 |
| Equity / liabilities | 6.216 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| COYA | Coya Therapeutics, Inc. | 2/9 | 5.24 | — | — |
| ACRS | Aclaris Therapeutics, Inc. | 2/9 | -18.21 | — | -58.2% |
| CRNX | Crinetics Pharmaceuticals, Inc. | 2/9 | 6.19 | — | — |
| ADAG | Adagene Inc. | 4/9 | -9.75 | — | — |
| ROIV | Roivant Sciences Ltd. | 1/9 | 18.07 | — | -71.6% |
| XENE | Xenon Pharmaceuticals Inc. | 2/9 | 6.89 | — | — |
| OVID | Ovid Therapeutics Inc. | 1/9 | 0.8 | — | -96.8% |
About Coya Therapeutics, Inc.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
FAQ
Is COYA financially healthy?
Coya Therapeutics, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does COYA pay a dividend?
No, Coya Therapeutics, Inc. does not currently pay a dividend.
How profitable is COYA?
In FY2025, Coya Therapeutics, Inc. had a net margin of -267.1% and a return on equity of -49.3%.
What is the analyst price target for COYA?
The average Wall-Street price target for Coya Therapeutics, Inc. is $15.21, about 224.4% above the recent price, from 7 analysts.
Is COYA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Coya Therapeutics, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.